John G Morikis bought $258K of Johnson & Johnson (JNJ)
Executed Nov 26 2025, disclosed Dec 1 2025, 5 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 1 2025), the stock returned +0.2% (delay-adjusted); from the execution session (Nov 26 2025), +0.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
John G Morikis (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Johnson & Johnson (JNJ). Across 1 priced purchase filing, the average 21-session return was +0.6% from execution and +0.2% from disclosure (delay-adjusted; derived). The largest single filing was $258K of JNJ (1,250 sh × $206.15, as filed), executed Nov 26 2025.
Healthcare · Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→